Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [31] Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
    Ciardullo, Stefano
    Vergani, Michela
    Perseghin, Gianluca
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [32] Diagnosis and Management of Type 2 Diabetic Kidney Disease
    Doshi, Simit M.
    Friedman, Allon N.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (08): : 1366 - 1373
  • [33] A narrative review of new treatment options for chronic kidney disease in type 2 diabetes
    Persson, Frederik
    Borg, Rikke
    Rossing, Peter
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [34] Treatment Patterns of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease in Colombia
    Machado, Manuel
    Gaviria-Mendoza, Andres
    Franco, Juan S.
    Forero, Maria D. R.
    Vizcaya, David
    Restrepo, Luis F. Valladales
    Machado-Alba, Jorge E.
    DIABETES, 2023, 72
  • [35] Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
    Ashjian, Emily
    Clarke, Megan
    Pogue, Kristen
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (23) : 1708 - 1721
  • [36] Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus
    Docherty, Neil G.
    le Roux, Carel W.
    NATURE REVIEWS NEPHROLOGY, 2020, 16 (12) : 709 - 720
  • [37] Finerenone (Kerendia) for the Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
    Stewart-Lynch, Autumn
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 305 - 306
  • [38] Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice
    G. Ermini
    C. Tosetti
    D. Zocchi
    M. Mandreoli
    M. T. Caletti
    G. Marchesini
    Journal of Endocrinological Investigation, 2019, 42 : 787 - 796
  • [39] Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice
    Ermini, G.
    Tosetti, C.
    Zocchi, D.
    Mandreoli, M.
    Caletti, M. T.
    Marchesini, G.
    Balduzzi, Antonio
    Bandi, Giulio
    Bassi, Beatrice
    Borghi, Paolo
    Brini, Loris
    Cammarata, Antonino
    Casadio, Roberto
    Cau, Roberto
    Cecchini, Lucia
    Del Vecchio, Aurelio
    De Vicariis, Maria Immacolata
    Ehrlich, Shirley
    Ermini, Giuliano
    Franco, Livio
    Ini, Angela
    La Fratta, Vincenzo
    Maccaferri, Marco
    Masi, Angelo
    Matra, Annunzio
    Gaito, Piero Mazzetti
    Mazzoni, Giampiero
    Monti, Dante
    Mori, Mara
    Oggianu, Massimo
    Palasciano, Maria
    Paternico, Anna
    Perrone, Fernando
    Pierallini, Roberto
    Quadrelli, Stefano
    Rubini, Stefano
    Salera, Marcello
    Serio, Alberto
    Silletti, Antonella
    Simoncini, Elisabetta
    Simoni, Luigi
    Speziali, Pietro
    Tosetti, Cesare
    Velona, Pietro
    Verri, Andrea
    Zisa, Domenico
    Zocchi, Donato
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 787 - 796
  • [40] Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus
    Neil G. Docherty
    Carel W. le Roux
    Nature Reviews Nephrology, 2020, 16 : 709 - 720